Needham initiated coverage on Evolus with a new price target
$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $10.00 → $16.00 | Equal Weight → Overweight | Barclays |
| 6/23/2022 | $18.00 | Buy | Needham |
| 5/12/2022 | $8.00 → $10.00 | Underweight → Equal Weight | Barclays |
| 1/20/2022 | $11.00 | Hold → Buy | Truist |
| 11/3/2021 | $22.00 → $15.00 | Buy | HC Wainwright & Co. |
10-Q - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
8-K - Evolus, Inc. (0001570562) (Filer)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of the presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. O
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced "esteem"), branded as Evolysse™ in the U.S. market. This certification marks a key regulatory milestone for Evolus, enabling it to commercially enter the dermal filler segment and doubling its addressable market outside the U.S. to $1.8 billion1. The CE Mark certification, through the new MDR process represents more stringent requirements, designed to ensure the safety, efficacy, and quality of
Achieves 2 Million Jeuveau® Redemptions Anticipates Launch of Club Evolus™, the first consumer membership program by a neurotoxin manufacturer, on November 4, 2024 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program. "The achievement of these milestones underscores the success of our strategy to democratize beauty and make aesthetics accessible to a new generation of consumers," said David Moatazedi, President and Chief Executive Officer. "Our easy
Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously
Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00
Barclays upgraded Evolus from Underweight to Equal Weight and set a new price target of $10.00 from $8.00 previously
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati
Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
4 - Evolus, Inc. (0001570562) (Issuer)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic r
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic
Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse® Lift and Smooth fillers, FDA Submission Expected within Next 90 Days Reaffirms Full-Year 2024 Net Revenue Guidance of $255 Million to $265 Million, Representing a 31% Growth Rate at the Top End Remains on Track to Achieve Projected Total Net Revenue Goal of At Least $700 Million by 2028 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the first quarter
SC 13G - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
SC 13G/A - Evolus, Inc. (0001570562) (Subject)
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the Evolysse™ Lift and Evolysse™ Smooth dermal filler products for the nasolabial fold (NLF).
Cantor Fitzgerald analyst Louise Chen reiterates Evolus (NASDAQ:EOLS) with a Overweight.
Launching in one of the five largest aesthetic toxin injectable markets in Europe1 as part of the company's geographic expansion strategyEvolus to provide Nuceiva® for direct order and delivery to Spanish medical aesthetics healthcare professionalsEvolus, Inc. (NASDAQ:EOLS), a performance beauty company focused on building an aesthetic portfolio, has commercially launched Nuceiva® (botulinum toxin type A) in Spain. The product is now available for direct order and delivery to Spanish medical aesthetics healthcare professionals.